Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases”

Talotta, Rossella

doi:10.1016/j.clim.2021.108665

Cited by 184 publications

(194 citation statements)

References 13 publications

Supporting

Mentioning

186

Contrasting

Unclassified

Order By: Relevance

“…This approach is based on the synthesis of RNA coding for the desired antigenic protein, but in order to avoid the degradation, RNA is encapsulated in nanoparticles or liposomes that deliver their content inside the target cells by endocytosis. Prior translation, RNA binds to pattern recognition receptors (especially Toll-like receptors) resulting in the activation of several proinflammatory signals including type I interferon response 9 . The up-regulation of these pathways is similar to what has been described in AIH (and other autoimmune diseases) and therefore we believe that more that casualty, the association between SARS-CoV-2 vaccines and AIH is causality.…”

Section: Financial Supportmentioning

confidence: 99%

Another case of autoimmune hepatitis after SARS-CoV-2 vaccination – still casualty?

Londoño

Gratacós‐Ginès

Sáez-Peñataro

2021

Journal of Hepatology

View full text Add to dashboard Cite

Section: Financial Supportmentioning

confidence: 99%

Another case of autoimmune hepatitis after SARS-CoV-2 vaccination – still casualty?

Londoño

Gratacós‐Ginès

Sáez-Peñataro

2021

Journal of Hepatology

View full text Add to dashboard Cite

“…The reactogenicity of COVID-19 mRNA vaccine in patient with immune-mediated diseases has not been addressed. Immunosuppressive agents prescribed to these patients alleviateadverse effects related to vaccine immunogenicity [33]. In addition to the mechanism of molecular mimicry, mRNA vaccines may trigger a cascade of immunological events that lead to the aberrant activation of the innate and acquired immune system [33].…”

Section: Discussionmentioning

confidence: 99%

“…Immunosuppressive agents prescribed to these patients alleviateadverse effects related to vaccine immunogenicity [33]. In addition to the mechanism of molecular mimicry, mRNA vaccines may trigger a cascade of immunological events that lead to the aberrant activation of the innate and acquired immune system [33]. In a novel case series in Egypt, COVID-19 infection was likely to induce primary fibromyalgia syndrome post-COVID [34].…”

Section: Discussionmentioning

confidence: 99%

Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt

et al. 2021

View full text Add to dashboard Cite

Objectives The aim of the present work was to explore the perspectives of Egyptian Rheumatology staff members as regards the coronavirus disease-19 (COVID-19) vaccine. Methods The survey is composed of 25 questions. Some questions were adapted from the global rheumatology alliance COVID-19 survey for patients. Results 187 rheumatology staff members across Egypt from 18 universities and authorizations actively participated with a valid response. The mean time needed to complete the survey was 17.7 ± 13 min. Participants were 159 (85%) females (F:M 5.7:1). One-third agreed that they will be vaccinated once available, 24.6% have already received at least one dose, 29.4% are unsure while 16% will not take it. Furthermore, 70.1% agreed that they will recommend it to the rheumatic diseases (RD) patients once available, 24.1% are not sure while 5.9% will not recommend it. RD priority to be vaccinated against COVID-19 in descending order include SLE (82.9%), RA (55.1%), vasculitis (51.3%), systemic sclerosis (39.6%), MCTD (31.6%), Behcet's disease (28.3%). The most common drugs to be avoided before vaccination included biologics (71.7%), DMARDs (44.4%), biosimilars (26.7%), IVIg (17.1%) and NSAIDs (9.1%). Conclusions The results of the study and specifically the low rate of acceptability are alarming to Egyptian health authorities and should stir further interventions to reduce the levels of vaccine hesitancy. As rheumatic disease patients in Egypt were not systematically provided with the vaccine till present, making the vaccine available could as well enhance vaccine acceptance. Further studies to investigate any possible side effects, on a large scale of RD patients are warranted.

show abstract

“…Concerns for the potential of new COVID-19 vaccine technologies to be associated with autoimmune phenomena are not new [ 95 ]. Some other concerns could also be discussed at a theoretical level [ 96 , 97 ].…”

Section: Thrombotic Events and Covid-19 Vaccinationmentioning

confidence: 99%

Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19

Cimolai

2021

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Advanced SARS-CoV-2 infections not uncommonly associate with the occurrence of silent or manifest thrombotic events which may be found as focal or systemic disease. Given the potential complexity of COVID-19 illnesses, a multifactorial causation is likely, but several studies have focused on infection-induced coagulopathy. Procoagulant states are commonly found in association with the finding of antiphospholipid antibodies. The correlation of the latter with thrombosis and/or clinical severity remains controversial. Although measures of antiphospholipid antibodies most commonly include assessments for lupus anticoagulant, anticardiolipin, and anti-ß2-glycoprotein-I antibodies, lesser common antibodies have been detected, and there remains speculation that other yet undiscovered autoimmune thrombotic events may yet be found. The recent discovery of post-vaccination thromboses associated with platelet factor 4 antibody has created another level of concern. The pathogenesis of antiphospholipid antibodies and their role in COVID-19-related thrombosis deserves further attention. The multifactorial nature of thrombosis associated with both infection and vaccination should continue to be studied as new events unfold. Even if a cause-and-effect relationship is variable at best, such dedicated research is likely to generate other valuable insights that are applicable to medicine generally.

show abstract

Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases”

Cited by 184 publications

References 13 publications

Another case of autoimmune hepatitis after SARS-CoV-2 vaccination – still casualty?

Another case of autoimmune hepatitis after SARS-CoV-2 vaccination – still casualty?

Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt

Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19

Contact Info

Product

Resources

About